2015 Antineoplastics

Therapeutic Uses

CETUXIMAB/PANITUMUMAB

• metastatic colon cancer

ERLOTINIB, GEFITINIB

• approved for use in metastatic non-small cell lung cancer (NSCLC) after failure of standard chemotherapies

• different populations experience varying efficacies:
  • 25% of NSCLC cases in Japan respond, but 10% of cases in US
  • non-smokers and broncho-alveolar subtype do better

→ having the "right" mutation (and we don't know what that is) means the difference between a "cure" and no response

• Drug cards
• Approaches
• Target Tyrosine Kinases
  • Bcr-Abl
    • Mechanism
    • Pharmacokinetics
    • Resistance
    • Therapeutic uses
    • Toxicities
  • EGFR
    • Mechanism
    • Therapeutic uses
    • Toxicities
    • Comparison
  • Block HER2
• Target altered processes
  • L-asparaginase
  • Proteosome inhibitors
    • Mechanism
    • Therapeutic uses
    • Toxicity
  • HDAC inhibitors
    • Mechanism
    • Toxicity